Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma

Human Pathology

Volumn 37, Issue 8, 2006, Pages 1111-1116

  Endo, Kazuhira ^a,b   Shirai, Akiko ^b   Furukawa, Mitsuru ^b   Yoshizaki, Tomokazu ^b  

^a Kouseiren Takaoka Hospital   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

AMFR; c Met; Ets 1; Prognosis; Tongue squamous cell carcinoma

Indexed keywords

SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL MOTILITY; DISEASE FREE SURVIVAL; EVALUATION; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; TUMOR RECURRENCE; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, CYTOKINE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746090453     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.03.020     Document Type: Article

References (30)

1. Liotta L.A., Mandler R., Murano G., et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A 83 (1986) 3302-3306
2. Maruyama K., Watanabe H., Shiozaki H., et al. Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma. Int J Cancer 64 (1995) 316-321
3. Nakamori S., Watanabe H., Kameyama M., et al. Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer 74 (1994) 1855-1862
4. Hirono Y., Fushida S., Yonemura Y., Yamamoto H., Watanabe H., and Raz A. Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. Br J Cancer 74 (1996) 2003-2007
5. Otto T., Bex A., Schmidt U., Raz A., and Rubben H. Improved prognosis assessment for patients with bladder carcinoma. Am J Pathol 150 (1997) 1919-1923
6. Ohta Y., Minato H., Tanaka Y., Go T., Oda M., and Watanabe Y. Autocrine motility factor receptor expression associates with tumor progression in thymoma. Int J Oncol 17 (2000) 259-264
7. Hammond D.E., Carter S., and Clague M.J. Met receptor dynamics and signalling. Curr Top Microbiol Immunol 286 (2004) 21-44
8. Gentile A., and Comoglio P.M. Invasive growth: a genetic program. Int J Dev Biol 48 (2004) 451-456
9. Silletti S., Watanabe H., Hogan V., Nabi I.R., and Raz A. Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res 51 (1991) 3507-3511
10. Gao C.F., Vande G., and Woude F. HGF/SF-Met signaling in tumor progression. Cell Res 15 (2005) 49-51
11. Gambarotta G., Boccaccio C., Giordano S., Ando M., Stella M.C., and Comoglio P.M. Ets up-regulates MET transcription. Oncogene 13 (1996) 1911-1917
12. Sobin LH, Wittekind Ch. TNM classification of malignant tumours 5th edition, International Union against Cancer, Wiley-Liss, Inc., New York. 1997.
13. Iezzoni J.C., Manahan L.J., Park C.S., and Brigati D.J. Recent advance in automated immunocytochemistry. J Histotechnol 16 (1993) 39-50
14. Yoshizaki T., Sato H., Maruyama Y., et al. Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer 79 (1997) 139-144
15. Nagai Y., Ishikawa O., Miyachi Y., and Watanabe H. Expression of autocrine motility factor receptor in cutaneous malignant melanoma. Dermatology 192 (1996) 8-11
16. Leemans C.R., Tiwari R., Nauta J.J., van der Waal I., and Snow G.B. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 73 (1994) 187-190
17. Leemans C.R., Tiwari R., Nauta J.J., van der Waal I., and Snow G.B. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71 (1993) 452-456
18. Yoshizaki T., Maruyama Y., Sato H., and Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 95 (2001) 44-50
19. Stetler-Stevenson W.G., Aznavoorian S., and Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9 (1993) 541-573
20. Guirguis R., Margulies I., Taraboletti G., Schiffmann E., and Liotta L. Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration. Nature 329 (1987) 261-263
21. Horikawa T., Sheen T.S., Takeshita H., Sato H., Furukawa M., and Yoshizaki T. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 159 (2001) 27-33
22. Gutman A., and Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 9 (1990) 2241-2246
23. Wasylyk C., and Wasylyk B. Oncogenic conversion alters the transcriptional properties of ets. Cell Growth Differ 3 (1992) 617-625
24. Gaire M., Magbanua Z., McDonnell S., McNeil L., and Lovett D.H. Matrisian LMStructure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 269 (1994) 2032-2040
25. Edwards D.R., Rocheleau H., Sharma R.R., et al. Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochim Biophys Acta 1171 (1992) 41-55
26. Rosen G.D., Barks J.L., Iademarco M.F., Fisher R.J., and Dean D.C. An intricate arrangement of binding sites for the Ets family of transcription factors regulates activity of the alpha 4 integrin gene promoter. J Biol Chem 269 (1994) 15652-15660
27. Nerlov C., Rorth P., Blasi F., and Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 6 (1991) 1583-1592
28. Taniguchi K., Yonemura Y., Nojima N., et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-Met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82 (1998) 2112-2122
29. Jiang W.G., Martin T.A., Parr C., Davies G., Matsumoto K., and Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 53 (2005) 35-69
30. Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65 (2005) 1479-1488